5.84
0.17%
0.010
Relay Therapeutics Inc stock is traded at $5.84, with a volume of 467.21K.
It is up +0.17% in the last 24 hours and down -10.26% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$5.85
Open:
$5.78
24h Volume:
467.21K
Relative Volume:
0.25
Market Cap:
$955.27M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-2.171
EPS:
-2.69
Net Cash Flow:
$-304.44M
1W Performance:
-0.68%
1M Performance:
-10.26%
6M Performance:
-16.76%
1Y Performance:
-22.07%
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Apr-13-23 | Initiated | Raymond James | Outperform |
Feb-03-23 | Initiated | Oppenheimer | Outperform |
Sep-30-22 | Initiated | Barclays | Equal Weight |
Sep-02-22 | Initiated | Stifel | Buy |
Jun-06-22 | Initiated | Jefferies | Underperform |
Feb-01-22 | Initiated | Berenberg | Buy |
Jul-21-21 | Initiated | BofA Securities | Buy |
Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
Nov-05-20 | Initiated | H.C. Wainwright | Buy |
Aug-10-20 | Initiated | Cowen | Outperform |
Aug-10-20 | Initiated | Goldman | Buy |
Aug-10-20 | Initiated | Guggenheim | Buy |
Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Where are the Opportunities in (RLAY) - Stock Traders Daily
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Relay Therapeutics (RLAY) to Release Earnings on Wednesday - MarketBeat
Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts - Investing.com India
Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts By Investing.com - Investing.com South Africa
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - The Manila Times
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, - EIN News
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Several Relay Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St
Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com Canada
Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase By Investing.com - Investing.com South Africa
Financial Snapshot: Analyzing Relay Therapeutics Inc (RLAY)’s Key Ratio Metrics - The Dwinnex
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
How did Relay Therapeutics Inc (RLAY) fare last session? - US Post News
Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC Wainwright - MarketBeat
Relay Therapeutics stock holds price target on FDA approval By Investing.com - Investing.com UK
Relay Therapeutics Inc (RLAY) receives a Buy rating from Jefferies - Knox Daily
(RLAY) Trading Report - Stock Traders Daily
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Relay Therapeutics Inc: Analyzing RLAY Stock Trends - The InvestChronicle
Relay Therapeutics Inc [NASDAQ: RLAY] Sees Increase in Stock Value - Knox Daily
Millennium Management LLC Purchases 921,271 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 4%Here's Why - MarketBeat
Its Stock Has Paid Off Big Time For Relay Therapeutics Inc - SETE News
Thrivent Financial for Lutherans Purchases New Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics Inc (RLAY) is a good investment, but the stock may be overvalued - US Post News
Ratio Analysis: Unpacking Relay Therapeutics Inc (RLAY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Relay Therapeutics Inc (RLAY) may enjoy gains as insiders got busy in the recent days - Knox Daily
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Marshall Wace LLP Purchases New Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics to Lay Off 10% of Workforce - BioSpace
Relay Therapeutics cuts 10% of staff after positive trial data - The Business Journals
insider Rahmer Peter sale 245 shares of Relay Therapeutics Inc [RLAY] - Knox Daily
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Relay Therapeutics executive sells shares worth over $2,200 By Investing.com - Investing.com Australia
Stocks of Relay Therapeutics Inc (RLAY) are poised to climb above their peers - SETE News
RLAY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Relay Therapeutics executive sells shares worth over $4,800 - Investing.com India
Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals
Relay Therapeutics executive sells shares worth over $2,200 - Investing.com
Relay Therapeutics executive sells shares worth over $4,800 By Investing.com - Investing.com Australia
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Catinazzo Thomas | Chief Financial Officer |
Oct 28 '24 |
Sale |
6.06 |
6,802 |
41,220 |
306,391 |
Catinazzo Thomas | Chief Financial Officer |
Oct 29 '24 |
Sale |
5.95 |
2,300 |
13,685 |
304,091 |
Bergstrom Donald A | President, R&D |
Oct 28 '24 |
Sale |
6.06 |
2,688 |
16,289 |
520,745 |
Adams Brian | Chief Legal Officer |
Oct 28 '24 |
Sale |
6.06 |
1,632 |
9,890 |
321,907 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):